

**PRESS RELEASE**

**29 January 2025 08:15:00 CET**

## **Saniona's CEO, Thomas Feldthus, participates in the Aktiespararna evening event on January 29**

**Saniona, a clinical-stage biopharmaceutical company, announces that the company's CEO, Thomas Feldthus, will participate at Aktiespararna on Wednesday, January 29th at 7:50 pm CET.**

Aktiespararna's interview will be available here: [aktiespararna.se](https://aktiespararna.se) from 7:50 pm CET on Wednesday, January 29th.

**For more information, please contact**

Thomas Feldthus, CEO, +45 22109957; [thomas.feldthus@saniona.com](mailto:thomas.feldthus@saniona.com)

**About Saniona**

Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona's epilepsy pipeline includes SAN2219, targeting acute repetitive seizures; and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine for obesity is Saniona's most advanced candidate and is out licensed to Medix in Mexico and Argentina. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona partners include Acadia Pharmaceuticals, Boehringer Ingelheim GmbH, Productos Medix S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market. For more information, visit [www.saniona.com](https://www.saniona.com).

**Attachments**

**Saniona's CEO, Thomas Feldthus, participates in the Aktiespararna evening event on January 29**